Sarepta Therapeutics
Utility Patents
Last updated:
List of all Sarepta Therapeutics patents 28 in total
| Status | Patent |
|---|---|
Grant | Utility: Compound and method for treating myotonic dystrophy Filling date: 6 Sep 2025 Issue date: 1 Feb 2022 |
Grant | Utility: Peptide oligonucleotide conjugates Filling date: 6 Sep 2025 Issue date: 18 Jan 2022 |
Grant | Utility: Peptide oligonucleotide conjugates Filling date: 6 Sep 2025 Issue date: 24 Aug 2021 |
Grant | Utility: Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene Filling date: 6 Sep 2025 Issue date: 13 Jul 2021 |
Grant | Utility: Methods and compounds for treatment of lymphocyte-related diseases and conditions Filling date: 6 Sep 2025 Issue date: 1 Jun 2021 |
Grant | Utility: Antisense-induced exon exclusion in myostatin Filling date: 6 Sep 2025 Issue date: 25 May 2021 |
Grant | Utility: Exon skipping oligomer conjugates for muscular dystrophy Filling date: 6 Sep 2025 Issue date: 11 May 2021 |
Grant | Utility: Processes for preparing phosphorodiamidate morpholino oligomers Filling date: 6 Sep 2025 Issue date: 30 Mar 2021 |
Grant | Utility: Processes for preparing phosphorodiamidate morpholino oligomers Filling date: 6 Sep 2025 Issue date: 16 Mar 2021 |
Grant | Utility: Compound and method for treating myotonic dystrophy Filling date: 6 Sep 2025 Issue date: 23 Feb 2021 |
Grant | Utility: Compositions for enhancing transport of molecules into cells Filling date: 6 Sep 2025 Issue date: 2 Feb 2021 |
Grant | Utility: Exon skipping compositions for treating muscular dystrophy Filling date: 6 Sep 2025 Issue date: 2 Feb 2021 |
Grant | Utility: Modified antisense oligomers for exon inclusion in spinal muscular atrophy Filling date: 6 Sep 2025 Issue date: 2 Feb 2021 |
Grant | Utility: Exon skipping oligomer conjugates for muscular dystrophy Filling date: 6 Sep 2025 Issue date: 12 Jan 2021 |
Grant | Utility: Processes for preparing oligomers Filling date: 6 Sep 2025 Issue date: 29 Dec 2020 |
Grant | Utility: Antisense-induced exon exclusion in type VII collagen Filling date: 6 Sep 2025 Issue date: 1 Dec 2020 |
Grant | Utility: Oligonucleotide analogues targeting human LMNA Filling date: 6 Sep 2025 Issue date: 3 Nov 2020 |
Grant | Utility: Exon skipping oligomer conjugates for muscular dystrophy Filling date: 6 Sep 2025 Issue date: 8 Sep 2020 |
Grant | Utility: Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups Filling date: 6 Sep 2025 Issue date: 1 Sep 2020 |
Grant | Utility: Exon skipping oligomer conjugates for muscular dystrophy Filling date: 6 Sep 2025 Issue date: 1 Sep 2020 |
Grant | Utility: Peptide oligonucleotide conjugates Filling date: 6 Sep 2025 Issue date: 9 Jun 2020 |
Grant | Utility: Antisense composition and method for treating muscle atrophy Filling date: 6 Sep 2025 Issue date: 21 Apr 2020 |
Grant | Utility: Induced exon inclusion in spinal muscle atrophy Filling date: 6 Sep 2025 Issue date: 3 Mar 2020 |
Grant | Utility: Splice-region antisense composition and method Filling date: 6 Sep 2025 Issue date: 14 Jan 2020 |
Grant | Utility: Peptide oligonucleotide conjugates Filling date: 6 Sep 2025 Issue date: 26 Nov 2019 |
Grant | Utility: Antisense antiviral compound and method for treating ss/RNA viral infection Filling date: 6 Sep 2025 Issue date: 19 Nov 2019 |
Grant | Utility: Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA Filling date: 6 Sep 2025 Issue date: 3 Sep 2019 |
Grant | Utility: Compositions for treating muscular dystrophy Filling date: 6 Sep 2025 Issue date: 30 Jul 2019 |
Showing 1 to 28 of 28 patents.